Cardiff Oncology, Inc.
NASDAQ:CRDFBiotechnology
Healthcare
$0.84 +2.12%
+$0.03 today
- Market cap
- $65.27M
- Beta
- 1.38
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$0.65
52W Low $1.16High $4.56
Volume 0.86M
Average 1.05M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$37.92M
FY 2025 · Annual
Investing Cash Flow
$1.34M
FY 2025 · Annual
-90.2% YoYFinancing Cash Flow
$2.58M
FY 2025 · Annual
-95.2% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (28.29M) | (38.7M) | (41.44M) | (45.43M) | (45.85M) |
| Depreciation & Amortization | 451K | 236K | 398K | 404K | 904K |
| Deferred Income Tax | 1.32M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 3.23M | 4.26M | 4.51M | 4.76M | 5.69M |
| Change in Working Capital | (1.79M) | (380K) | 6.57M | 3.17M | 2.18M |
| Accounts Receivables | (215K) | (236K) | 483K | (484K) | 591K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 719K | 1.35M | 2.83M | 2.99M | 2.2M |
| Other Working Capital | (2.29M) | (1.49M) | 3.25M | 671K | (614K) |
| Other Non-Cash Items | 2.03M | 772K | (921K) | (598K) | (848K) |
| Operating Cash Flow | (23.04M) | (33.82M) | (30.89M) | (37.69M) | (37.92M) |
| Capital Expenditures | (205K) | (892K) | (582K) | (80K) | (44K) |
| Acquisitions (Net) | 205K | (114K) | 0 | 0 | 0 |
| Purchases of Investments | (174.39M) | (91.23M) | (70.08M) | (23.56M) | (71.12M) |
| Sales of Investments | 43.14M | 130.27M | 106.86M | 37.37M | 73.25M |
| Other Investing Activities | (205K) | 114K | 0 | 0 | (744K) |
| Investing Cash Flow | (131.45M) | 38.15M | 36.2M | 13.73M | 1.34M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 34.19M | 75K | 0 | 53.41M | 2.58M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | (24K) | (414K) | 0 | 0 | 0 |
| Other Financing Activities | 1.29M | 414K | 0 | 373K | 0 |
| Financing Cash Flow | 35.45M | 75K | 0 | 53.78M | 2.58M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (119.04M) | 4.4M | 5.31M | 29.82M | (34M) |
| Free Cash Flow | (23.25M) | (34.71M) | (31.47M) | (37.77M) | (37.97M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$45.9M
+ D&A$904.0K
+ Stock-Based Comp$5.7M
+ Deferred Tax$0
+ Working Capital$2.2M
- Other Non-Cash-$848.0K
= Operating Cash Flow-$37.9M
- Capex-$44.0K
= Free Cash Flow-$38.0M
Analysis
FY2025 free cash flow is -$38.0M. FCF conversion is 82.8% of net income. Operating cash flow was -$37.9M, with capex of -$44.0K. The largest bridge item is Stock-Based Comp at $5.7M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 12, 2026 | |
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 3 | Initial statement of beneficial ownership | Oct 27, 2026 | |
| 8-K | Current report | Oct 27, 2026 | |
| 8-K | Current report | Oct 22, 2026 |
Does CRDF generate free cash flow?
Cardiff Oncology, Inc. (CRDF) generated -$37.97M of free cash flow in fiscal 2025.
How much operating cash flow does CRDF produce?
Operating cash flow was -$37.92M, before capital expenditures of $44,000.00.
Continue the stock analysis
Jump to another research area for this company.